NRM and REL cumulative incidence estimates (36-month) from a competing risk model, estimated separately for both conditioning regimens (standard myeloablative and RIC) and 3 disease status categories at transplantation. The three categories are “untreated,” “treated; in CR1,” and “treated; not in CR1.”